These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37935020)

  • 1. In brief: Empagliflozin (Jardiance) for chronic kidney disease.
    Med Lett Drugs Ther; 2023 Nov; 65(1689):183-184. PubMed ID: 37935020
    [No Abstract]   [Full Text] [Related]  

  • 2. In brief: Expanded heart failure indication for dapagliflozin (Farxiga).
    Med Lett Drugs Ther; 2023 Jun; 65(1679):101-102. PubMed ID: 37339090
    [No Abstract]   [Full Text] [Related]  

  • 3. In brief: Expanded heart failure indication for empagliflozin (Jardiance).
    Med Lett Drugs Ther; 2022 Apr; 64(1648):57. PubMed ID: 35436772
    [No Abstract]   [Full Text] [Related]  

  • 4. Sotagliflozin (Inpefa) for heart failure.
    Med Lett Drugs Ther; 2023 Jul; 65(1681):114-116. PubMed ID: 37460142
    [No Abstract]   [Full Text] [Related]  

  • 5. Bexagliflozin (Brenzavvy) - A fifth SGLT2 inhibitor for type 2 diabetes.
    Med Lett Drugs Ther; 2023 Aug; 65(1683):130-132. PubMed ID: 37651295
    [No Abstract]   [Full Text] [Related]  

  • 6. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
    Johnston R; Uthman O; Cummins E; Clar C; Royle P; Colquitt J; Tan BK; Clegg A; Shantikumar S; Court R; O'Hare JP; McGrane D; Holt T; Waugh N
    Health Technol Assess; 2017 Jan; 21(2):1-218. PubMed ID: 28105986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin (Jardiance) for heart failure with reduced ejection fraction.
    Med Lett Drugs Ther; 2021 Nov; 63(1636):171-172. PubMed ID: 35085205
    [No Abstract]   [Full Text] [Related]  

  • 8. Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):55-56. PubMed ID: 29635266
    [No Abstract]   [Full Text] [Related]  

  • 9. Canagliflozin (Invokana). A "me-too" of the dangerous dapagliflozin.
    Prescrire Int; 2015 Feb; 24(157):33-5. PubMed ID: 25802910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In patients with moderate chronic kidney disease, including non-diabetic patients, does empagliflozin provide renal and cardiovascular benefit compared to placebo, and is it safe?].
    Lanthier L; Viau-Trudel A; Plourde ME; Cauchon M
    Rev Med Interne; 2023 Jun; 44(6):319-320. PubMed ID: 37045658
    [No Abstract]   [Full Text] [Related]  

  • 11. Empagliflozin (Jardiance) for heart failure.
    Med Lett Drugs Ther; 2020 Nov; 62(1611):177-178. PubMed ID: 33438858
    [No Abstract]   [Full Text] [Related]  

  • 12. Empagliflozin (Jardiance) for type 2 diabetes in children.
    Med Lett Drugs Ther; 2023 Aug; 65(1683):e137. PubMed ID: 37651298
    [No Abstract]   [Full Text] [Related]  

  • 13. Ertugliflozin for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):70-72. PubMed ID: 29667948
    [No Abstract]   [Full Text] [Related]  

  • 14. Empagliflozin (Jardiance). Type 2 diabetes: no rush to use this drug.
    Prescrire Int; 2016 Jun; 25(172):145-8. PubMed ID: 27486640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ▼ Empagliflozin, diabetes and outcomes.
    Drug Ther Bull; 2016 Jul; 54(7):78-81. PubMed ID: 27417322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
    Barnett AH; Mithal A; Manassie J; Jones R; Rattunde H; Woerle HJ; Broedl UC;
    Lancet Diabetes Endocrinol; 2014 May; 2(5):369-84. PubMed ID: 24795251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sodium glucose co-transporter 2 inhibitors on the kidney.
    de Albuquerque Rocha N; Neeland IJ; McCullough PA; Toto RD; McGuire DK
    Diab Vasc Dis Res; 2018 Sep; 15(5):375-386. PubMed ID: 29963920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison chart: SGLT2 inhibitors.
    Med Lett Drugs Ther; 2020 Nov; 62(1611):e2-e4. PubMed ID: 33429417
    [No Abstract]   [Full Text] [Related]  

  • 20. In brief: Dapagliflozin (Farxiga) for chronic kidney disease.
    Med Lett Drugs Ther; 2021 Jul; 63(1629):115. PubMed ID: 34544107
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.